# Systemic Lupus Erythematosus & Lupus Nephritis ๐Ÿงฌ # Systemic Lupus Erythematosus & Lupus Nephritis Comprehensive Guide to SLE Diagnosis, Classification, and Management ๐Ÿ“Š 2019 EULAR/ACR Criteria ๐Ÿ”ฌ ISN/RPS Classification ๐Ÿ’Š Evidence-Based Treatment ๐ŸŽ† Emerging Therapies 2025 ๐Ÿ‘ฉ Special Populations ## ๐Ÿ“š Overview of Systemic Lupus Erythematosus **Systemic Lupus Erythematosus (SLE)** is a chronic, multi-system autoimmune disease characterized by loss of tolerance to nuclear antigens, leading to immune complex formation and tissue damage. Lupus nephritis occurs in 50-70% of SLE patients and is a major cause of morbidity and mortality. ### โš ๏ธ Clinical Significance - **Prevalence:** 20-150 per 100,000, with higher rates in women (9:1 ratio) and certain ethnicities - **Kidney involvement:** 50-70% of SLE patients develop lupus nephritis - **Prognosis:** 10-year survival \>95% with appropriate treatment - **ESRD risk:** 10-15% progress to end-stage renal disease without proper management ## SLE Pathophysiology: From Genes to Disease ### ๐Ÿงฌ Molecular Pathogenesis #### 1. Genetic Predisposition HLA associations, complement deficiencies, immune regulation gene variants #### 2. Environmental Triggers UV exposure, infections (EBV), drugs, stress #### 3. Loss of Tolerance Defective apoptosis, increased cell death, autoantigen exposure #### 4. Autoantibody Production Anti-dsDNA, Anti-Sm, Antiphospholipid, Anti-C1q #### 5. Immune Complex Formation In situ and circulating immune complexes #### 6. Tissue Damage Complement activation, inflammation, organ damage ### ๐Ÿ”ฌ Key Pathophysiologic Concepts #### Type II & III Hypersensitivity - Antibody-mediated tissue damage - Immune complex deposition - Complement activation - Inflammatory cascade #### Interferon-ฮฑ Pathway - Plasmacytoid dendritic cell activation - Interferon signature in SLE - Tubuloreticular inclusions in kidneys - Target for new therapies #### Molecular Mimicry - Anti-dsDNA cross-reactivity - ฮฑ-actinin in glomerular basement membrane - Direct kidney targeting - Nephritogenic potential ## 2019 EULAR/ACR SLE Classification Criteria ### ๐Ÿ“‹ Criteria Overview The 2019 EULAR/ACR criteria represent a significant improvement over previous classification systems, with enhanced specificity and clinical relevance. The weighted scoring system better reflects the relative importance of different clinical and laboratory features. #### Entry Criterion **ANA โ‰ฅ 1:80** on HEp-2 cells (required for classification) #### Classification Threshold **โ‰ฅ10 points** for SLE classification #### Weighted Scoring Points range from **2-10** based on specificity ### ๐Ÿงฎ Interactive SLE Criteria Calculator Click on criteria present in your patient to calculate the SLE classification score: #### Constitutional Domain Fever 2 points #### Hematologic Domain Leukopenia (\<4,000/mmยณ) 3 points Thrombocytopenia (\<100,000/mmยณ) 4 points Autoimmune hemolysis 4 points #### Neuropsychiatric Domain Delirium 2 points Psychosis 3 points Seizure 5 points #### Mucocutaneous Domain Non-scarring alopecia 2 points Oral ulcers 2 points Subacute cutaneous OR discoid lupus 4 points Acute cutaneous lupus (malar rash) 6 points #### Musculoskeletal Domain Joint involvement 6 points #### Renal Domain Proteinuria \>0.5g/24h 4 points Renal biopsy Class II or V lupus nephritis 8 points Renal biopsy Class III or IV lupus nephritis 10 points #### Serosal Domain Pleural or pericardial effusion 5 points Acute pericarditis 6 points #### Immunologic Domain Low C3 OR low C4 3 points Low C3 AND low C4 4 points Anti-phospholipid antibodies 2 points Anti-dsDNA OR Anti-Sm antibodies 6 points Total Score: 0 points\ ANA โ‰ฅ1:80 required for entry. โ‰ฅ10 points needed for SLE classification. ## ๐Ÿงฌ SLE Autoantibody Profiles & Clinical Correlations | Autoantibody | Frequency in SLE | Clinical Associations | Disease Activity Correlation | Clinical Utility | |----|----|----|----|----| | **ANA** | 95-98% | Screening test, multiple patterns | No correlation | Entry criterion, excludes SLE if negative | | **Anti-dsDNA** | 60-70% | Lupus nephritis, more severe disease | **Strong correlation** | Disease monitoring, nephritis prediction | | **Anti-Sm** | 20-25% | SLE-specific, less nephritis | No correlation | Diagnosis confirmation, high specificity | | **Anti-SSA/Ro52** | 30-40% | Neonatal lupus, CHB, photosensitivity | Mild correlation | Pregnancy counseling essential | | **Anti-SSA/Ro60** | 25-35% | Sicca symptoms, subacute cutaneous lupus | No correlation | Secondary Sjรถgren's overlap | | **Anti-SSB/La** | 15-20% | Neonatal lupus, less nephritis | No correlation | Often with anti-SSA/Ro | | **Anti-RNP** | 30-40% | MCTD overlap, less nephritis | No correlation | Mixed connective tissue disease | | **Anti-C1q** | 30-40% | Active nephritis, more severe disease | **Strong correlation** | Nephritis activity monitoring | | **Antiphospholipid** | 30-50% | Thrombosis, pregnancy complications | No correlation | Anticoagulation decisions | | **Anti-ribosomal P** | 10-20% | Neuropsychiatric lupus, psychosis | Activity correlation | CNS lupus evaluation | ### ๐ŸŽฏ Clinical Pearls for Autoantibody Interpretation - **Anti-dsDNA monitoring:** Rising levels often precede clinical flares by 4-8 weeks - **Complement consumption:** Low C3 AND C4 indicates classical pathway activation (SLE pattern) - **Anti-C1q utility:** More specific for active nephritis than anti-dsDNA alone - **Pregnancy screening:** Anti-SSA/Ro and anti-SSB/La essential before conception - **Antiphospholipid syndrome:** Requires clinical events plus persistent antibodies ## ISN/RPS Lupus Nephritis Classification ### ๐Ÿ”ฌ Classification Overview The International Society of Nephrology/Renal Pathology Society (ISN/RPS) 2003 classification system provides standardized terminology for lupus nephritis, enabling consistent treatment decisions and prognosis assessment. #### Class I: Minimal Mesangial **Frequency:** 5-10% **Findings:** Normal light microscopy, minimal mesangial deposits on EM **Clinical:** Normal kidney function, minimal proteinuria **Treatment:** No specific therapy needed **Prognosis:** Excellent #### Class II: Mesangial Proliferative **Frequency:** 10-20% **Findings:** Mesangial hypercellularity, mesangial deposits **Clinical:** Mild proteinuria, occasional hematuria **Treatment:** Supportive care, monitor for progression **Prognosis:** Good, may progress to higher classes #### Class III: Focal Proliferative **Frequency:** 15-25% **Findings:** \<50% glomeruli involved, endocapillary proliferation **Clinical:** Nephritic syndrome, variable kidney function **Treatment:** Immunosuppression based on activity **Prognosis:** Variable, depends on activity and chronicity #### Class IV: Diffuse Proliferative **Frequency:** 40-50% **Findings:** โ‰ฅ50% glomeruli involved, +/- crescents **Clinical:** Most severe, mixed nephritic-nephrotic **Treatment:** Aggressive immunosuppression required **Prognosis:** Guarded without treatment, good with therapy **Subclassification:** - **IV-S (Segmental):** \<50% of capillary tuft involved - **IV-G (Global):** โ‰ฅ50% of capillary tuft involved #### Class V: Membranous **Frequency:** 15-20% **Findings:** Subepithelial deposits, "spike and dome" appearance **Clinical:** Nephrotic syndrome, normal kidney function initially **Treatment:** Immunosuppression for high-risk disease **Prognosis:** Good short-term, risk of progression #### Class VI: Advanced Sclerosing **Frequency:** 5-10% **Findings:** \>90% glomerulosclerosis **Clinical:** Advanced CKD, irreversible damage **Treatment:** CKD management, transplant preparation **Prognosis:** Poor for kidney recovery ### ๐ŸŽฏ Activity and Chronicity Scoring #### Activity Index (0-24) - Endocapillary proliferation (ร—1) - Neutrophil infiltration (ร—1) - Subendothelial hyaline deposits (ร—1) - Fibrinoid necrosis (ร—2) - Cellular crescents (ร—2) - Interstitial inflammation (ร—1) #### Chronicity Index (0-12) - Glomerular sclerosis (ร—1) - Fibrous crescents (ร—1) - Tubular atrophy (ร—1) - Interstitial fibrosis (ร—1) **Clinical Relevance:** Activity index โ‰ฅ12 or chronicity index โ‰ฅ4 indicates worse prognosis and may require more aggressive treatment. ## Evidence-Based Lupus Nephritis Treatment ### ๐ŸŽฏ Treatment Philosophy Modern lupus nephritis treatment follows a two-phase approach: **induction therapy** to achieve remission and **maintenance therapy** to prevent relapse while minimizing toxicity. Treatment selection is individualized based on nephritis class, patient factors, and regional preferences. ### Phase 1: Induction Therapy (0-6 months) **Goal:** Achieve complete or partial remission **Duration:** Maximum 6 months **Indications:** Class III, IV, or V lupus nephritis #### ๐Ÿšจ Emergency Measures (Severe Class IV) - **IV Methylprednisolone:** 0.5-1g daily ร— 3 days - **Plasmapheresis:** Consider if crescents \>50% or anti-GBM positive - **Dialysis support:** If uremic or volume overloaded #### ๐Ÿฅ‡ Mycophenolate Mofetil (Preferred) **Dose:** 2-3g daily in divided doses **Advantages:** - Equivalent efficacy to cyclophosphamide - Better fertility preservation - Lower infection risk - No hemorrhagic cystitis risk **Monitoring:** CBC weekly ร— 4, then monthly **Evidence:** ALMS trial showed non-inferiority #### Cyclophosphamide (Alternative) **Dose:** 0.5-1g/mยฒ monthly ร— 6 doses OR 1.5-2mg/kg daily **Advantages:** - Rapid onset of action - Effective for severe disease - Long track record of efficacy **Disadvantages:** - Fertility toxicity (major concern) - Hemorrhagic cystitis - Secondary malignancy risk - Higher infection rates **Monitoring:** CBC weekly, urinalysis monthly #### ๐ŸŒŸ Voclosporin (Lupkynis) - FDA Approved 2021 **Dose:** 23.7mg twice daily with food + MMF 1g BID **Revolutionary Advantages:** - **Superior efficacy:** AURORA trial: 40.8% complete response vs 22.5% MMF alone - **First approved CNI:** Specifically for lupus nephritis - **Steroid-sparing:** Allows faster corticosteroid tapering - **Consistent levels:** Improved pharmacokinetics vs traditional CNIs **Monitoring:** Trough levels (target 10-15 ng/mL), eGFR, BP, electrolytes **Evidence:** First positive CNI trial in lupus nephritis #### Traditional Calcineurin Inhibitors **Options:** Tacrolimus 0.1mg/kg/day or Cyclosporine 4-5mg/kg/day **Indications:** - Class V (membranous) lupus nephritis - MMF intolerance - Alternative when voclosporin unavailable **Limitations:** Less evidence in lupus nephritis vs voclosporin **Monitoring:** Drug levels, kidney function, blood pressure #### ๐Ÿ’Š Corticosteroid Protocol - **Initial:** Prednisone 0.5-1mg/kg/day (max 60-80mg) - **Duration:** 4-6 weeks at full dose - **Tapering:** Reduce by 25% every 2-4 weeks to 10-15mg/day - **Goal:** โ‰ค7.5mg/day by 6 months ### Phase 2: Maintenance Therapy (6+ months) **Goal:** Prevent relapse, minimize drug toxicity **Duration:** Minimum 3 years, often longer **Entry criteria:** Achievement of partial or complete remission #### ๐Ÿฅ‡ Mycophenolate Mofetil (First-Line) **Dose:** 1-2g daily **Advantages:** - Superior to azathioprine in some studies - Lower relapse rates - Better long-term kidney survival **Evidence:** MAINTAIN nephritis trial #### Azathioprine (Alternative) **Dose:** 1.5-2.5mg/kg daily **Advantages:** - Pregnancy-compatible - Long-term safety data - Cost-effective **Considerations:** - Check TPMT enzyme activity - Higher relapse rates vs MMF #### Calcineurin Inhibitors **Role:** Alternative maintenance option **Indications:** - MMF/AZA intolerance - Combination protocols - Class V nephritis **Limitations:** Nephrotoxicity, hypertension #### ๐Ÿ“Š Response Assessment Criteria ##### Complete Remission - Proteinuria \<0.5g/24h - Normal/stable kidney function - Inactive urinary sediment ##### Partial Remission - โ‰ฅ50% reduction in proteinuria - Proteinuria \<3g/24h - Stable kidney function ##### Treatment Failure - No improvement at 6 months - Worsening kidney function - Need for rescue therapy ### Adjunctive Therapies #### ๐Ÿ›ก๏ธ Hydroxychloroquine **Dose:** 200-400mg daily **Benefits:** - Reduced flare rates - Cardiovascular protection - Antithrombotic effects - Improved survival **Monitoring:** Annual ophthalmologic exams #### ๐Ÿซ€ ACE Inhibitors/ARBs **Indications:** Proteinuria \>0.5g/24h **Benefits:** - Nephroprotection - Reduced proteinuria - Blood pressure control - Cardiovascular protection **Goal:** BP \<130/80 mmHg #### ๐Ÿฆด Bone Health **Calcium:** 1200mg daily **Vitamin D:** 1000-2000 IU daily **Bisphosphonates:** Consider if: - Postmenopausal - Long-term steroids - T-score โ‰ค-2.5 #### ๐Ÿ’‰ Vaccinations **Before immunosuppression:** - Live vaccines if possible - Pneumococcal (PCV13 + PPSV23) - Influenza (annual) - COVID-19 (up to date) **Avoid:** Live vaccines during immunosuppression ## Special Populations: Young Women with SLE ### ๐Ÿ‘ฉ Unique Considerations for Young Women Young women with SLE face unique challenges including fertility preservation, pregnancy planning, contraception selection, and long-term bone health. Comprehensive care requires addressing these issues proactively. ### ๐Ÿคฐ Pregnancy and Lupus Nephritis #### Pre-Conception Counseling (Essential) ##### Optimal Timing - SLE quiescent โ‰ฅ6 months - Complete/partial remission - Prednisone โ‰ค10mg daily - Stable kidney function ##### Medication Adjustments - **Switch MMF to AZA** 3 months before conception - Continue hydroxychloroquine - Optimize steroid dose - Ensure pregnancy-safe HTN meds ##### Essential Testing - Anti-SSA/Ro and anti-SSB/La - Antiphospholipid antibodies - Complement levels - Baseline kidney function #### ๐Ÿ“‹ Pregnancy-Safe Medications #### โœ… SAFE in Pregnancy - **Azathioprine:** First-line maintenance - **Hydroxychloroquine:** Continue throughout - **Prednisone:** Safe but minimize dose - **Cyclosporine:** Alternative option - **Tacrolimus:** Limited data but acceptable #### โŒ AVOID in Pregnancy - **Mycophenolate:** Teratogenic - **Cyclophosphamide:** Teratogenic - **Methotrexate:** Teratogenic - **ACE inhibitors:** Fetotoxic - **ARBs:** Fetotoxic #### ๐Ÿ”„ Lupus Nephritis Flare vs. Preeclampsia | Feature | Lupus Nephritis Flare | Preeclampsia | Both Can Coexist | |----|----|----|----| | **Timing** | Any gestational age | Usually \>20 weeks | Overlap possible | | **Anti-dsDNA** | Rising levels | Stable or declining | May be confusing | | **Complement** | Low C3, C4 | Normal or high | Key differentiator | | **Uric acid** | Normal or slightly elevated | Markedly elevated | Helpful distinction | | **RBC casts** | Present | Absent | Strongly supports glomerular bleeding; identify the cause clinically and with biopsy when indicated | | **Platelets** | Variable | Often low | Not discriminatory | ### ๐Ÿ›ก๏ธ Contraception in SLE #### โœ… Preferred Options - **Progestin-only pills:** No thrombosis risk - **Levonorgestrel IUD:** Highly effective - **Copper IUD:** Hormone-free option - **Barrier methods:** Condoms, diaphragm - **Depot medroxyprogesterone:** Consider bone health #### โš ๏ธ Use with Caution - **Combined oral contraceptives:** Avoid if antiphospholipid antibodies positive - **Estrogen-containing methods:** Increased thrombosis risk - **Consideration:** May be acceptable in stable disease without aPL antibodies ### ๐Ÿƒโ€โ™€๏ธ Fertility Preservation #### High-Risk Factors - Cyclophosphamide exposure - Age \>35 years - Prior fertility issues - Family history of early menopause #### Preservation Options - **Oocyte cryopreservation:** Before treatment - **Embryo cryopreservation:** If partner available - **GnRH agonists:** During cyclophosphamide (limited evidence) - **Ovarian tissue cryopreservation:** Experimental #### Counseling Points - Discuss early in treatment planning - Fertility consultation before cyclophosphamide - Alternative treatments to preserve fertility - Regular AMH monitoring ## ๐Ÿ“Š Disease Activity Monitoring & Long-term Management ### ๐ŸŽฏ Monitoring Strategy Effective lupus nephritis management requires systematic monitoring of disease activity, treatment response, and medication toxicity. Early detection of flares allows for prompt intervention and better outcomes. #### ๐Ÿ“… Monitoring Schedule **Induction phase:** Monthly visits **Maintenance phase:** Every 3-6 months **Stable remission:** Every 6-12 months #### ๐Ÿงช Laboratory Tests **Routine:** CBC, CMP, UA, UPC ratio **Activity markers:** Anti-dsDNA, C3, C4 **If active:** Anti-C1q, CH50 #### ๐Ÿ’Š Drug Monitoring **MMF:** CBC, GI tolerance **CNI:** Drug levels, kidney function **HCQ:** Annual eye exams #### ๐ŸŽฏ Treatment Goals **Proteinuria:** \<0.5g/24h (complete remission) **Kidney function:** Stable or improving eGFR **Serology:** Normalizing complement, declining anti-dsDNA ### ๐Ÿšจ Flare Recognition & Management #### Early Warning Signs - Rising anti-dsDNA levels - Declining complement (C3, C4) - Increasing proteinuria - New systemic symptoms - Rising creatinine #### Flare Management - **Mild flare:** Increase prednisone - **Moderate flare:** IV methylprednisolone - **Severe flare:** Repeat induction protocol - **Consider:** Rituximab for refractory disease ## Emerging & Revolutionary Therapies in Lupus Nephritis ### ๐ŸŽ† The Future of Lupus Nephritis Treatment The landscape of lupus nephritis treatment is rapidly evolving with breakthrough therapies showing unprecedented efficacy. These novel approaches target specific pathways and offer hope for superior outcomes with reduced toxicity. #### ๐ŸŒŸ Obinutuzumab (Gazyva) - Game Changer **Mechanism:** Glycoengineered anti-CD20 type II monoclonal antibody **Advantages over Rituximab:** - **Enhanced B-cell depletion:** Superior direct cell death and antibody-dependent cellular cytotoxicity - **Clinical efficacy:** Improved renal responses versus placebo on background standard therapy in NOBILITY and REGENCY; treatment choice depends on eligibility, infection risk, kidney function, and current guidance. - **Faster onset:** More rapid B-cell depletion compared to rituximab - **Glycoengineering:** Modified Fc region for enhanced binding to immune effector cells **Dosing:** 1000mg IV on days 1, 8, 15 of cycle 1, then 1000mg on day 1 of subsequent cycles **Clinical evidence:** NOBILITY was a phase 2 placebo-controlled trial of obinutuzumab added to standard therapy. The phase 3 [REGENCY trial (2025)](https://pubmed.ncbi.nlm.nih.gov/39927615/) subsequently reported complete renal response at week 76 in 46.4% versus 33.1% with placebo, both on background mycophenolate and glucocorticoids. These trials did not directly compare obinutuzumab with rituximab. **Status:** Under FDA review for lupus nephritis indication #### ๐ŸŽ† Belimumab (Benlysta) - Precision Targeting **Mechanism:** Human monoclonal antibody against BLyS/BAFF (B-lymphocyte stimulator) **Unique Advantages:** - **Targeted B-cell regulation:** Blocks B-cell survival signals without complete depletion - **FDA approved for SLE:** Only biologic approved for systemic lupus - **Add-on therapy:** Enhances efficacy when combined with standard treatment - **Steroid-sparing:** Allows significant corticosteroid reduction **Dosing:** 10mg/kg IV every 2 weeks ร— 3 doses, then every 4 weeks **Clinical Evidence:** BLISS-LN trial showed improved response rates in lupus nephritis **Current Use:** FDA-approved for SLE, expanding use in lupus nephritis #### ๐Ÿงฌ CAR-T Cell Therapy - Revolutionary Potential **Mechanism:** Genetically modified autologous T-cells targeting CD19+ B-cells **Breakthrough Concept:** - **"Reset" immune system:** Deep B-cell depletion followed by immune reconstitution - **Durable remissions:** Potential for long-term drug-free remission - **Severe disease:** Reserved for refractory, life-threatening cases - **One-time treatment:** Single infusion with lasting effects **Clinical Status:** Early-phase trials in severe autoimmune diseases **Results:** Preliminary data shows sustained remissions in refractory SLE **Challenges:** Cytokine release syndrome, cost, specialized centers required **Future:** May revolutionize treatment of severe lupus nephritis #### ๐ŸŒฑ Additional Emerging Therapies **Anifrolumab (Saphnelo):** - Type I interferon receptor antagonist - FDA-approved for non-renal SLE - Under investigation for lupus nephritis **Voclosporin (Lupkynis) - FDA Approved 2021:** - **Revolutionary approach:** First CNI specifically approved for lupus nephritis - **AURORA trial success:** 40.8% complete response vs 22.5% with MMF alone - **Combination therapy:** Used with low-dose MMF (1g BID) + corticosteroids - **Steroid-sparing:** Allows faster corticosteroid tapering - **Dosing:** 23.7mg twice daily with food - **Monitoring:** Target trough levels 10-15 ng/mL **Dual B-cell targeting:** - Combination obinutuzumab + belimumab - Targeting multiple B-cell pathways - Enhanced efficacy in trials ### ๐ŸŽฏ Treatment Selection Algorithm for 2025 #### First-Line Induction (Updated 2025) - **Option 1:** MMF + corticosteroids (traditional) - **Option 2:** Voclosporin + MMF (superior efficacy) - **Young women:** Prioritize fertility preservation - **Enhanced approach:** Early belimumab add-on #### Refractory Disease - **Second-line:** Obinutuzumab - **Combination:** Dual B-cell targeting - **Severe cases:** Consider CAR-T referral #### Steroid Minimization - **Goal:** โ‰ค5mg prednisone daily - **Strategy:** Early biologic introduction - **Monitor:** B-cell depletion markers ### ๐Ÿ”ญ Clinical Trial Considerations For patients with severe or refractory lupus nephritis, clinical trial participation should be strongly considered. The rapid pace of therapeutic development means that cutting-edge treatments may be available through research protocols before FDA approval. **Key Trial Resources:** - ClinicalTrials.gov for active lupus nephritis studies - Lupus Clinical Trials Consortium - National Institutes of Health (NIH) protocols - Industry-sponsored phase II/III trials ## ๐ŸŒ Health Disparities in Lupus Nephritis ### โš–๏ธ Racial and Ethnic Disparities #### African Americans - **Prevalence:** 3-4ร— higher than Caucasians - **Age of onset:** Earlier (teens-20s) - **Severity:** More severe nephritis - **ESRD risk:** 4ร— higher progression rate - **Response:** Lower response to cyclophosphamide #### Hispanic/Latino - **Prevalence:** 2-3ร— higher than Caucasians - **Severity:** More severe disease - **Access:** Barriers to specialist care - **Outcomes:** Higher mortality rates #### Asian Populations - **Genetic factors:** HLA associations - **Clinical features:** More Class V nephritis - **Treatment response:** Variable by subgroup ### ๐ŸŽฏ Addressing Disparities #### Clinical Considerations - Consider more aggressive initial treatment in high-risk populations - MMF may be preferred over cyclophosphamide in African Americans - Higher MMF doses (3g vs 2g daily) if tolerated - Earlier nephrology referral #### Social Determinants - Address medication adherence barriers - Consider transportation and work limitations - Culturally competent care - Language interpretation services ## ๐Ÿ’Ž Clinical Pearls for SLE & Lupus Nephritis #### ๐Ÿ”ฌ Diagnostic Pearls - **"Full-house" nephritis:** IgG, IgM, IgA, C3, C1q all positive = lupus nephritis - **C1q deposition:** 90% specific for lupus nephritis - **Tubuloreticular inclusions:** Interferon-ฮฑ signature on EM - **Anti-dsDNA monitoring:** Rising levels precede flares by 4-8 weeks #### ๐Ÿ’Š Treatment Pearls - **MMF + voclosporin option:** Superior to MMF alone (AURORA trial), especially for severe disease - **MMF monotherapy limitations:** May be insufficient for Class IV nephritis - consider combination therapy - **Obinutuzumab:** Placebo-controlled NOBILITY and REGENCY trials support adding obinutuzumab to standard therapy in their studied populations; they do not establish superiority to rituximab. - **Belimumab add-on strategy:** Consider early in treatment to enhance steroid-sparing - **Voclosporin (Lupkynis):** FDA-approved novel CNI for lupus nephritis (2021) - **CAR-T future:** Revolutionary potential for refractory disease - **Steroid minimization goal:** โ‰ค5mg prednisone daily with biologics - **Hydroxychloroquine:** Continue throughout pregnancy and treatment #### ๐Ÿ‘ฉ Women's Health Pearls - **Fertility planning:** Switch MMF to AZA 3 months before conception - **Contraception:** Avoid estrogen if antiphospholipid antibodies positive - **Pregnancy monitoring:** Low complement differentiates flare from preeclampsia - **Bone health:** Calcium + Vitamin D for all steroid users #### ๐Ÿ“Š Monitoring Pearls - **Response criteria:** \>50% proteinuria reduction at 6 months - **Complete remission:** Proteinuria \<0.5g/24h - **B-cell monitoring:** CD19+ counts with obinutuzumab/rituximab therapy - **Flare prediction:** Serial anti-dsDNA + complement levels - **Biologic efficacy:** Earlier response seen with novel agents - **Drug levels:** Monitor CNI trough levels (voclosporin target 10-15 ng/mL) ## ๐Ÿ”— Integration with Case 7: Lupus Nephritis This comprehensive SLE module directly supports **Case 7: Lupus Nephritis in Young Woman**, providing the foundational knowledge needed to understand the complex case presentation, diagnostic approach, and treatment decisions. The case applies these concepts in a real clinical scenario. #### ๐Ÿ“‹ Case Application - 2019 EULAR/ACR criteria scoring - ISN/RPS Class IV classification - MMF vs cyclophosphamide selection - Young women considerations #### ๐Ÿงช Laboratory Integration - Anti-dsDNA and complement interpretation - "Full-house" nephritis pattern - Activity vs chronicity indices - Treatment response monitoring #### ๐Ÿ’Š Treatment Decisions - Evidence-based induction protocols - Fertility preservation strategies - Contraception counseling - Long-term maintenance planning [๐Ÿ“‹ Study Case 7: Lupus Nephritis](https://urinenephrology.org/2025_UDPA_Lectures_Live/cases/case7_enhanced.html) [๐ŸŽ† Emerging Therapies Section](https://urinenephrology.org/2025_UDPA_Lectures_Live/glomerulonephritis/SLE.html#emerging-therapies) [๐Ÿ”ฌ Return to Glomerulonephritis Main](https://urinenephrology.org/2025_UDPA_Lectures_Live/glomerulonephritis/index.html) ## ๐Ÿ“š Sources 1. **Rovin BH, Adler SG, Barratt J, et al; KDIGO Glomerular Diseases Work Group.** KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. *Kidney Int.* 2021;100(4S):S1-S276. [PMID: 34556256](https://pubmed.ncbi.nlm.nih.gov/34556256/). *โ€” Lupus nephritis chapter โ€” induction (MMF or IV cyclophosphamide ยฑ voclosporin / belimumab) and maintenance.* 2. **Rovin BH, Teng YKO, Ginzler EM, et al; AURORA 1 Investigators.** Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. *Lancet.* 2021;397(10289):2070-2080. [PMID: 33971155](https://pubmed.ncbi.nlm.nih.gov/33971155/). *โ€” AURORA 1 voclosporin in active LN; CRR at week 52 favored voclosporin (40.8% vs 22.5%).* 3. **Furie R, Rovin BH, Houssiau F, et al.** Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis (BLISS-LN). *N Engl J Med.* 2020;383(12):1117-1128. [PMID: 32937045](https://pubmed.ncbi.nlm.nih.gov/32937045/). *โ€” BLISS-LN โ€” belimumab + standard of care vs SOC; primary efficacy renal response 43% vs 32%.* 4. Furie R, Aroca G, Cascino MD, et al. B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2022;81(1):100โ€“107. [PubMed](https://pubmed.ncbi.nlm.nih.gov/34615636/). 5. **Houssiau FA, Vasconcelos C, D'Cruz D, et al.** Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial. *Arthritis Rheum.* 2002;46(8):2121-2131. [PMID: 12209517](https://pubmed.ncbi.nlm.nih.gov/12209517/). *โ€” Euro-Lupus low-dose IV cyclophosphamide regimen (500 mg q2w ร— 6 doses).* 6. **Appel GB, Contreras G, Dooley MA, et al; Aspreva Lupus Management Study Group.** Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. *J Am Soc Nephrol.* 2009;20(5):1103-1112. [PMID: 19369404](https://pubmed.ncbi.nlm.nih.gov/19369404/). *โ€” ALMS induction trial โ€” MMF non-inferior to IV cyclophosphamide; preferred in non-Caucasians.* 7. **Aringer M, Costenbader K, Daikh D, et al.** 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. *Arthritis Rheumatol.* 2019;71(9):1400-1412. [PMID: 31385462](https://pubmed.ncbi.nlm.nih.gov/31385462/). *โ€” EULAR/ACR 2019 SLE classification criteria.* --- [Website version](https://urinenephrology.org/2025_UDPA_Lectures_Live/glomerulonephritis/SLE.html) ยท Markdown synchronized October 3, 2026.